ADGM vs ATRC vs NVCR vs BEAT vs IRTC

For growth investors, iRhythm Technologies, Inc.

(IRTC) is the stronger pick with 26. 2% revenue growth year-over-year, versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). Analysts rate AtriCure, Inc. (ATRC) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, iRhythm Technologies, Inc.

(IRTC) delivered a total return of +56. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: IRTC returned +363. 2% versus ADGM's -89. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), iRhythm Technologies, Inc.

(IRTC) is the lower-risk stock at 0. 73β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 196% more volatile than IRTC relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 5% for iRhythm Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), iRhythm Technologies, Inc.

(IRTC) is pulling ahead at 26. 2% versus -10. 3% for Adagio Medical Holdings, Inc. (ADGM). On earnings-per-share growth, the picture is similar: AtriCure, Inc. grew EPS 74. 7% year-over-year, compared to 15. 1% for HeartBeam, Inc.. Over a 3-year CAGR, IRTC leads at 22. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

HeartBeam, Inc.

(BEAT) is the more profitable company, earning 0. 0% net margin versus -199. 9% for Adagio Medical Holdings, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BEAT leads at 0. 0% versus -232. 3% for ADGM. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AtriCure, Inc.

(ATRC) trades at 428. 7x forward P/E versus 27422. 7x for iRhythm Technologies, Inc. — 26994. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, iRhythm Technologies, Inc.

(IRTC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 73), +363. 2% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 15 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (IRTC: +363. 2%, NVCR: +38. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ADGM is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock; BEAT is a small-cap quality compounder stock; IRTC is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.